SynthesisBMC nephrology2019
Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis.
Synthesis in BMC nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Cardiovascular Outcomes of Uric Acid Lowering Medications: A Meta-Analysis.Current cardiology reports · 2024Pooled it
- Serum Uric Acid and Cardiovascular or All-Cause Mortality in Peritoneal Dialysis Patients: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Uric acid in CKD: has the jury come to the verdict?Journal of nephrology · 2020Pooled it
- Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.Clinical rheumatology · 2020Pooled it
- Baseline Uric Acid-to-HDL Cholesterol Ratio Predicts Peritoneal Membrane Failure in Peritoneal Dialysis Patients.Journal of clinical medicine · 2026Article
- Factors influencing serum uric acid levels and their impact on cardiovascular risk in patients with pediatric chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2026Article
- A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome.Drug design, development and therapy · 2026Review
- Major adverse cardiovascular events and hyperuricemia as an effect-modifying factor in kidney transplant recipients.World journal of transplantation · 2025Article
- Article
- SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes.Frontiers in endocrinology · 2025Review
- Prevalence and clinical characteristics of hyperuricemia among patients with chronic kidney disease under haemodialysis in a tertiary care center: a cross-sectional study.Annals of medicine and surgery (2012) · 2024Article
- The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.Journal of clinical medicine · 2024Article
- Uric Acid Is Not Associated With Cardiovascular Health in Youth With Type 1 Diabetes: SEARCH for Diabetes in Youth Study.The Journal of clinical endocrinology and metabolism · 2024Article
- The association between dietary antioxidant quality score and uric acid related mortality in patients with chronic kidney disease.Frontiers in nutrition · 2024Article
- Interaction between anemia and hyperuricemia in the risk of all-cause mortality in patients with chronic kidney disease.Frontiers in endocrinology · 2024Article
- The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Review
- Dysuricemia-A New Concept Encompassing Hyperuricemia and Hypouricemia.Biomedicines · 2023Review
- Concentration of serum uric acid in patients with Renal Artery Stenosis and Hypertension prEdict Future nephropathy and death: C-RASHEF study.Journal of clinical hypertension (Greenwich, Conn.) · 2023Article
- The Singapore Experience With Uncontrolled Gout: Unmet Needs in the Management of Patients.Cureus · 2023Review
- Predictive Value of Collagen Biomarkers in Advanced Chronic Kidney Disease Patients.Biomolecules · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConflicting results have been reported from studies evaluating serum uric acid (SUA) levels as an independent risk factor for cardiovascular mortality in patients with chronic kidney disease (CKD).
methodsWe systematically searched MEDLINE, Web of Science, and bibliographies of retrieved articles to identify studies reporting on the association between SUA levels and cardiovascular mortality in patients with CKD. Random-effects models were used to calculate the pooled hazard ratios (HR) and corresponding 95% confidence intervals (CI).
resultsWe included 11 studies with an overall sample of 27,081 patients with CKD in this meta-analysis. By meta-analysis, restricted to 7 studies (n = 11,050), patients with the highest SUA were associated with an increased risk of cardiovascular mortality (HR 1.47, 95% CI 1.11-1.96) compared with patients with the lowest SUA. There was no indication of publication bias or significant heterogeneity (I
conclusionsHigher SUA levels are associated with significantly increased risk of cardiovascular mortality in patients with CKD. More designed studies, especially randomized controlled trials, should be conducted to determine whether high SUA levels is a potentially modifiable risk factor for cardiovascular mortality in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.